Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.47 |
| ▸ | NPC1 | O15118 | 5/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2387189 | 0.77 | RAB9A (0.42) | RAB9ANPC1HTTHPGDHDAC3 | |
| SCHEMBL5585822 | 0.72 | NPC1 (0.51) | RAB9ANPC1HTTHPGDHDAC3 | |
| SCHEMBL10841553 | 0.70 | NPC1 (0.59) | RAB9ANPC1HPGDHDAC3CA12 | |
| SCHEMBL554490 | 0.70 | RAB9A (0.59) | RAB9ANPC1HPGDHDAC3CA12 | |
| SCHEMBL9117090 | 0.69 | RAB9A (0.51) | RAB9ANPC1HPGDHDAC3HDAC1 | |
| SCHEMBL5155207 | 0.69 | NPC1 (0.57) | RAB9ANPC1HPGDHDAC3CA12 | |
| SCHEMBL497521 | 0.69 | NPC1 (0.57) | RAB9ANPC1HPGDHDAC3CA12 | |
| SCHEMBL289886 | 0.69 | NPC1 (0.57) | RAB9ANPC1HPGDHDAC3CA12 | |
| SCHEMBL11145110 | 0.69 | NPC1 (0.57) | RAB9ANPC1HPGDHDAC3CA12 | |
| SCHEMBL4644708 | 0.69 | NPC1 (0.57) | RAB9ANPC1HPGDHDAC3CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575148-B2 | Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers | ABBOTT HEALTHCARE PRODUCTS B.V. (NL) | 2013-11-05 | — | — | US | disclosed |
| EP-2376501-A1 | SPIRO AZEPANE-OXAZOLIDINONES AS Kv1.3 POTASSIUM CHANNEL BLOCKERS | Abbott Healthcare Products B.V. (NL) | 2011-10-19 | — | — | EP | disclosed |
| US-20110237569-A1 | SPIRO AZEPANE-OXAZOLIDINONES AS Kv1.3 POTASSIUM CHANNEL BLOCKERS | ABBOTT HEALTHCARE PRODUCTS B.V. (NL) | 2011-09-29 | — | — | US | disclosed |
| WO-2010066840-A1 | SPIRO AZEPANE-OXAZOLIDINONES AS Kv1.3 POTASSIUM CHANNEL BLOCKERS | SOLVAY PHARMACEUTICALS B.V. (NL) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237569-A1 | SPIRO AZEPANE-OXAZOLIDINONES AS Kv1.3 POTASSIUM CHANNEL BLOCKERS | KCNA3, KCND3, KCNK3 | RAB9A 2041/4885NPC1 2332/4885HTT 2159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.